Oncothyreon (NASDAQ: [[ticker:ONTY]]), the Seattle-based developer of cancer drugs, said today it has raised $15 million by securing commitments from investors to buy new shares and warrants. The financing came one day after demand surged for Oncothyreon sales when it said a small group of lung cancer patients had long-lasting responses after taking Stimuvax, the immune-boosting vaccine therapy Oncothyreon is co-developing with Merck KGaA. Oncothyreon’s main business these days is actually in developing cancer drugs, not vaccines, as described in this March profile on Xconomy.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
